Le Lézard
Classified in: Health, Science and technology, Business
Subject: CXP

ORHub Announces Placement on Microsoft Azure Marketplace and Microsoft AppSource


NEWPORT BEACH, Calif., Dec. 17, 2018 /PRNewswire/ -- ORHub, Inc. (OTC: ORHB) (the "Company" or "ORHub"), a SaaS-based healthcare data analytics company uniquely focused on the business of surgery to improve the profitability of health systems, hospitals and ambulatory surgery centers (ASCs), today announces placement on Microsoft Azure Marketplace and Microsoft AppSource to expand sales lead generation.

(PRNewsfoto/ORHub, Inc.)

Microsoft Azure Marketplace is where existing Azure customers can find new products to facilitate hospital IT staff to support internal customers. 

Microsoft AppSource is a business marketplace where Microsoft's internal sales teams are incentivized to find solutions for their customers.

"Since ORHub was born from the Microsoft for Start Ups program, these marketplaces are natural extensions of our sales lead generation program to complement ORHub's direct sales force and distribution," said Colt Melby, Chief Executive Officer of ORHub.  "We look forward to continuing our partnership with Microsoft to automate sales and showcase Surgical Spotlighttm as we scale nationally." 

Spotlighttm is a differentiated platform that links OR efficiency metrics to cost data for materials and labor.  Implementation of the Surgical Spotlighttm custom dashboard is lightweight and doesn't require EHR integration, costly analysts or complicated software.  Its cloud-based data feeds populate dynamic dashboards that can be used by administrators, surgeons and nurses. 

About ORHub, Inc.
ORHub, born from the Microsoft for Start-Ups program, is an advanced surgical software provider focused on the Business of Surgery through the foundation of electronic data capture at the point-of-surgical care to improve workflow, simplify work processes and access data intelligence. The Company's suite of products serves the needs of the health care industry including providers, patients, the government and medical device vendors. ORHub provides a cloud-based software solution that captures information before, during and after surgery, filling a void in the current surgical information infrastructure and providing the first process to capture and measure the surgical process -- evolving Big Data into Intelligent Digital Data.

Hospitals and surgeons can make data-driven decisions to improve business profitability and the quality of patient care. This innovative technology results in hospitals understanding costs and identifying areas of cost reductions, as well as results in increased accountability, analytics, improved efficiencies, and compliance with existing government regulations. ORHub has offices in Tempe, Arizona; Newport and Laguna Beach, California; Bellevue, Washington; and Jacksonville, Florida.

For more information, visit www.ORHub.com
To view a previously released Microsoft Case Study on HOI and ORHub visit:
https://customers.microsoft.com/en-us/story/hoi-health-azure

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the Company believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, it can give no assurances that its expectations will be attained. Such statements are inherently uncertain, and actual results and activities may differ materially from those estimated or projected. Certain factors that can affect the Company's ability to achieve its anticipated results include, among others, uncertainties inherent in the development of a new software product business.

ORHub Contact: 

Jason Brown, Shareholder Communications 

[email protected] 

714-228-5667

Media Relations:

Cathy Loos, Senior Media Relations Specialist

[email protected]

347.334.4135

 

SOURCE ORHub, Inc.


These press releases may also interest you

at 08:05
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:05
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage...

at 08:02
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative...

at 08:00
Citius Pharmaceuticals Inc. ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive...

at 08:00
Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio N. Gordan, MD will serve as a panelist at the 2024 Oncology Fellows & Faculty Forum in Miami, sponsored by PrecisCa and the Community Oncology Alliance...

at 08:00
Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced its participation at two prestigious medical conferences: the American...



News published on and distributed by: